In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Expands MorphoSys Alliance To Include Antibodies For Infectious Disease

This article was originally published in PharmAsia News

Executive Summary

Japan's third-largest drug maker Daiichi Sankyo expanded its alliance with German biotech MorphoSys to include discovery and development of therapeutic antibodies for hospital-acquired infections. The earlier collaboration was focused solely on oncology

You may also be interested in...



Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say

TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas

Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say

TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas

Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery

Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development

Related Content

UsernamePublicRestriction

Register

SC070145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel